SEC For	m 4																			
FORM 4 UNI				NITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549													OMB APPROVAL			
Section 16. Form 4 or Form 5 obligations may continue. See					NT OF CHANGES IN BENEFICIAL OWNE ed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940									HIP	Estim	OMB Number: 3235-0287 Estimated average burden hours per response: 0.5		1		
1. Name and Address of Reporting Person* Rabinowitz Michael (Last) (First) (Middle) 1185 AVENUE OF THE AMERICAS, THIRD					2. Issuer Name and Ticker or Trading Symbol ORAMED PHARMACEUTICALS INC. [ORMP] 3. Date of Earliest Transaction (Month/Day/Year) 08/04/2021								(Che	Relationship of Reporting Person(s) to Issuer leck all applicable) Director 10% Owner X Officer (give title Other (specify below) Chief Commercial Officer						
FLOOR (Street) NEW YORK, NY 10036 (City) (State) (Zip)					4. If Amendment, Date of Original Filed (Month/Day/Year) Solution State of Original Filed (Month/Day/Year)								ividual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person							
Table I - Non-Deriv 1. Title of Security (Instr. 3) 2. Trans Date					1			a. a. b. b. c. c. <thc.< th=""> c. <thc.< th=""> <thc.< td="" th<=""><td>(A) or</td><td>5. Amoun</td><td></td><td colspan="2">of 6. Ow Form:</td><td>7. Nature of Indirect</td></thc.<></thc.<></thc.<>				(A) or	5. Amoun		of 6. Ow Form:		7. Nature of Indirect			
				(Month/Day/Year)		if any (Month/Day/Yea		Code (Amount		(A) or (D)	Price	Beneficia Owned Fo Reported Transacti (Instr. 3 a	lly ollowing on(s)	(D) or	r Indirect str. 4)	Beneficial Ownership (Instr. 4)		
Common Stock ⁽¹⁾ 08/04					2021 ⁽²⁾		A		100,0		A	\$0	100,000			D				
			Table II - I (uired, D s, option						Owned				1		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Da if any (Month/Day/Y	Code	saction e (Instr.	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exe Expiration (Month/Da		nd 7. Title and Amo of Securities Underlying Derivative Secu (Instr. 3 and 4)		ecurity	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)			
				Code	e V	(A)	(D)	Date Exercisabl		expiration Date	Title		imount r lumber f Shares		(Instr. 4)					
Stock Option (right to buy)	\$15.1	08/04/2021		A		100,000		(3)	0	8/04/2031	Comr Stoo		.00,000	\$0	100,0	00	D			

Explanation of Responses:

1. Represents common stock underlying Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock.

2. The RSUs will vest as follows: 33,333 shall vest if the closing price per share of the Issuer's common stock will be \$15 for at least 20 days, 33,333 shall vest if the closing price per share of the Issuer's common stock will be \$25 for at least 20 days, and 33,334 shall vest if the Issuer consummates an arm's length licensing or other strategic transaction, that includes its phase 3 oral insulin product, for no less than \$50,000,000 in upfront cash (including proceeds from any upfront stock equity purchase).

3. The Stock Options will vest in five installments as follows: 12,500 shall vest on December 31, 2021, 25,000 shall vest on each of December 31, 2022, December 31, 2023 and December 31, 2024, and 12,500 shall vest on August 4, 2025.

/s/ Michael Rabinowitz 08/06/2021 Date

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.